Professor Manali Kamdar speaks about Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma.

Video: https://congressreport.eu/scientific-contents/interview:results-randomized-phase-3-transform-study